AstraZeneca (AZN) said Monday that its drug, Imfinzi, was recommended for approval in the European Union as a monotherapy for limited-stage small cell lung cancer in adults.
The company said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use was based on phase 3 trial results, demonstrating that Imfinzi reduced the risk of death by 27%, compared to placebo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.